South Korea Approves Phase 1 Trials of COVID-19 Anti-Parasite Drug South Korea Approves Phase 1 Trials of COVID-19 Anti-Parasite Drug
Drugmaker Daewoong Pharmaceutical said on Monday that it had received regulatory approval in South Korea for Phase 1 clinical trials of its anti-parasitic niclosamide drug to treat COVID-19 patients.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
More News: Clinical Trials | COVID-19 | Infectious Diseases | Intensive Care | Parasitic Diseases | Parasitology | South Korea Health